Comparative Effectiveness

Fillmore and his collaborators employ large-scale clinical data to evaluate the comparative effectiveness of oncologic therapies in prostate cancer and multiple myeloma. His research identifies specific patient subgroups that derive maximal benefit from particular regimens, such as the superiority of docetaxel rechallenge over cabazitaxel in select prostate cancer populations and the efficacy of intensive triplet therapy for frail patients with multiple myeloma. These studies provide evidence to optimize treatment selection based on patient comorbidities, age, and prior treatment responses.